medigraphic.com
ISSN 1527-3172 (Digital)

2022, Número 1

<< Anterior Siguiente >>

MEDICC Review 2022; 24 (1)


Innate immune stimulation should not be overlooked in post-exposure prophylaxis and early therapy for coronavirus infections

Aguilar-Rubido JC, Pentón-Arias E, Fazle Akbar SM

Idioma: Ingles.
Referencias bibliográficas: 36
Paginas: 70-75
Archivo PDF: 217.71 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kikkert M. Innate immune evasion by humanrespiratory RNA viruses. J Innate Immun. 2020Jan–Feb;12(1):4–20.

  2. Metcalf TU, Cubas RA, Ghneim K, CartwrightMJ, Grevenynghe JV, Richner JM, et al. Globalanalyses revealed age-related alterations ininnate immune responses after stimulation ofpathogen recognition receptors. Aging Cell. 2015Jun;14(3):421–32.

  3. Neumann-Podczaska A, Al-Saad SR, KarbowskiLM, Chojnicki M, Tobis S, Wieczorowska-Tobis K.COVID 19 - Clinical picture in the elderly population:a qualitative systematic review. Aging Dis.2020 Jul 23;11(4):988–1008.

  4. Kumaki Y, Salazar AM, Wandersee MK, BarnardDL. Prophylactic and therapeutic intranasaladministration with an immunomodulator,Hiltonol® (Poly IC:LC), in a lethal SARS-CoVinfectedBALB/c mouse model. Antiviral Res.2017 Mar;139:1–12.

  5. Zhao J, Wohlford-Lenane C, Zhao J, Fleming E,Lane TE, McCray PB Jr, et al. Intranasal treatmentwith poly(I•C) protects aged mice fromlethal respiratory virus infections. J Virol. 2012Nov;86(21):11416–24.

  6. Pentón-Arias E, Aguilar-Rubido JC. Cubanprophylactic and therapeutic vaccines for controllinghepatitis B. MEDICC Rev [Internet].2021 Jan [cited 2021 Feb 7];23(1):21–9. DOI:10.37757/MR2021.V23.N1.6. Available at:https://mediccreview.org/estadisticas/ppp.php?y=2021&v=1&p=21

  7. Al-Mahtab M, Akbar SM, Aguilar JC, Uddin MH,Khan MS, Rahman S. Therapeutic potential of acombined hepatitis B virus surface and core antigenvaccine in patients with chronic hepatitis B.Hepatol Int. 2013 Oct;7(4):981–9.

  8. Akbar SMF, Yoshida O, Chen S, Cesar AJ, AbeM, Matsuura B, et al. Immune modulator andantiviral potential of dendritic cells pulsed withboth hepatitis B surface antigen and core antigenfor treating chronic HBV infection. Antivir Ther.2010;15(6):887–95.

  9. Lobaina Y, Hardtke S, Wedemeyer H, Aguilar JC,Schlaphoff V. In vitro stimulation with HBV therapeuticvaccine candidate Nasvac activates B and Tcells from chronic hepatitis B patients and healthydonors. Mol Immunol. 2015 Feb;63(2):320–7.

  10. Aguilar JC, Lobaina Y, Muzio V, García D, PentónE, Iglesias E, et al. Development of a nasal vaccinefor chronic hepatitis B infection that uses the abilityof hepatitis B core antigen to stimulate a strongTh1 response against hepatitis B surface antigen.Immunol Cell Biol. 2004 Oct;82(5):539–46.

  11. Fleites YA, Aguiar J, Cinza Z, Bequet-RomeroM, Marrero E, Vizcaíno M, et al. HeberNasvac, atherapeutic vaccine for chronic hepatitis B, stimulateslocal and systemic markers of innate immunity:potential use in SARS-CoV-2 post-exposureprophylaxis. Euroasian J Hepatogastroenterol.2021 Jul–Dec;11(2):59–70.

  12. Clinical trials of HeberNasvac and Mambisaindexed at the Cuban Registry of Clinical Trials(RPCEC00000326-En; RPCEC00000353-En; RPCEC00000356-En; RPCEC00000345-En andRPCEC00000382-En) [Internet]. Havana:National Clinical Trials Coordinating Center –CENCEC (CU); c2020–2021 [cited 2021 Aug 21].Available at: https://rpcec.sld.cu/trials/. Spanish.

  13. Akbar SMF, Mahtab MA, Aguilar JC, Uddin MH,Khan SI, Yoshida O, et al. Repurposing NASVAC,A Hepatitis B Therapeutic Vaccine, forpre-and post-exposure prophylaxis of SARSCoV-2 infection. J Antivir Antiretrovir. 2021May;13(S20):1000004.

  14. Aguilar JC, Aguiar J, inventors; Center for GeneticEngineering and Biotechnology, assignee. Viralnucleoprotein and formulations thereof. Cuba patentapplication CU 2020-0028. 2020 April 20.

  15. Aguilar JC. A therapeutic perspective of theimmunological function of the liver. Biotecnol Apl.2010 Jan;27(1):10–8.

  16. Prasad K, Khatoon F, Rashid S, Ali N, A AsmariAF, Ahmed MZ, et al. Targeting hub genes andpathways of innate immune response in COVID-19: a network biology perspective. Int J BiolMacromol. 2020 Nov 15;163:1–8.

  17. Aich P, Wilson HL, Kaushik RS, Potter AA, BabiukLA, Griebel P. Comparative analysis of innateimmune responses following infection of newborncalves with bovine rotavirus and bovine coronavirus.J Gen Virol. 2007 Oct;88(Pt 10):2749–61.

  18. Zhu Q, Egelston C, Gagnon S, Sui Y, BelyakovIM, Klinman DM, et al. Using 3 TLR ligandsas a combination adjuvant induces qualitativechanges in T cell responses needed forantiviral protection in mice. J Clin Invest. 2010Feb;120(2):607–16.

  19. Zhu Q, Egelston C, Vivekanandhan A, UematsuS, Akira S, Klinman DM, et al. Toll-like receptorligands synergize through distinct dendritic cellpathways to induce T cell responses: implicationsfor vaccines. Proc Natl Acad Sci U S A. 2008 Oct;105(42):16260–5.

  20. Cooper A, Tal G, Lider O, Shaul Y. Cytokineinduction by the hepatitis B virus capsid in macrophagesis facilitated by membrane heparansulfate and involves TLR2. J Immunol. 2005Sep;175(5):3165–76.

  21. Lee BO, Tucker A, Frelin L, Sallberg M, JonesJ, Peters C, et al. Interaction of the hepatitis Bcore antigen and the innate immune system. JImmunol. 2009 Jun;182(11):6670–81.

  22. Mao T, Israelow B, Lucas C, Vogels CBF, FedorovaO, Breban MI, et al. A stem-loop RNA RIG-Iagonist confers prophylactic and therapeutic protectionagainst acute and chronic SARS-CoV-2infection in mice. bioRxiv 448754 [Preprint]. 2021Jun 17 [cited 2021 Jun 26]. Available at: https://doi.org/10.1101/2021.06.16.448754

  23. Thorne LG, Bouhaddou M, Reuschl AK, Zuliani-Alvarez L, Polacco B, Pelin A, et al. Evolution ofenhanced innate immune evasion by the SARSCoV-2 B.1.1.7 UK variant. bioRxiv 446826 [Preprint].2021 Jun 7 [cited 2021 Jun 16]. Availableat: https://doi.org/10.1101/2021.06.06.446826.

  24. Curtis N, Sparrow A, Ghebreyesus TA, NeteaMG. Considering BCG vaccination to reducethe impact of COVID-19. Lancet. 2020May;395(10236):1545–6.

  25. Iturriaga C, Eiffl er N, Aniba R, Ben-Othman R,Perez-Mateluna G, Meyer JKV, et al. A clusterrandomized trial of interferon ß-1a for thereduction of transmission of SARS-Cov-2: protocolfor the Containing Coronavirus Disease 19trial (ConCorD-19). BMC Infect Dis. 2021 Aug13;21(1):814.

  26. Nasalferon [Recombinant Human InterferonAlpha 2b]. Summary of Product Features.[Internet]. Havana: Center for State Control ofMedicines, Equipment and Medical Devices -CECMED (CU) ; c2021 [cited 2021 Aug 21].Available at: https://www.cecmed.cu/registro/rcp/nasalferon-Interferon-alfa-2b-humano-recombinante. Spanish.

  27. Pereda R, González D, Blas Rivero H, RiveroJC, Pérez A, Del Rosario López L, et al. Therapeuticeff ectiveness of interferon-α2b againstCOVID-19: the Cuban experience. J InterferonCytokine Res. 2020 Sep;40(9):438–42.

  28. Sánchez Ramón S, Manzanares M, CandelasG. MUCOSAL anti-infections vaccines: beyondconventional vaccines. Reumatol Clin (Engl Ed).2020 Jan–Feb;16(1):49–55. English, Spanish.

  29. Altimmune Receives Award from U.S. Departmentof Defense to Fund Phase 1/2 Clinical Trialof T-COVID™ in Outpatients with Early COVID-19 [Internet]. Gaithersburg: Altimmune Headquarters;2020 Jun 29 [cited 2021 Jun 29]; [about2 p.]. Available at: https://www.globenewswire.com/news-release/2020/06/29/2054563/0/en/Altimmune-Receives-Award-from-U-S-Department-of-Defense-to-Fund-Phase-1-2-Clinical-Trial-of-T-COVID-in-Outpatients-with-Early-COVID-19.html

  30. Arunachalam PS, Wimmers F, Mok CKP, PereraRAPM, Scott M, Hagan T, et al. Systems biologicalassessment of immunity to mild versussevere COVID-19 infection in humans. Science.2020 Sep 4;369(6508):1210–20.

  31. Sariol CA, Martínez MI, Rivera F, RodríguezIV, Pantoja P, Abel K, et al. Decreased denguereplication and an increased anti-viral humoralresponse with the use of combined Toll-likereceptor 3 and 7/8 agonists in macaques. PLoSOne. 2011 Apr 29;6(4):e19323.

  32. Yuan MM, Xu YY, Chen L, Li XY, Qin J, Shen Y.TLR3 expression correlates with apoptosis, proliferationand angiogenesis in hepatocellular carcinomaand predicts prognosis. BMC Cancer. 2015Apr 9;15:245. DOI: 10.1186/s12885-015-1262-5

  33. Aguilar JC, Rodríguez EG. Vaccine adjuvantsrevisited. Vaccine. 2007 May 10;25(19):3752–62.

  34. Sui Y, Berzofsky JA. Myeloid cell-mediated trainedinnate immunity in mucosal AIDS vaccine development.Front Immunol. 2020 Feb 28;11:315.DOI: 10.3389/fi mmu.2020.00315

  35. Netea MG, Giamarellos-Bourboulis EJ, Domínguez-Andrés J, Curtis N, van Crevel R, van deVeerdonk FL, et al. Trained immunity: a toolfor reducing susceptibility to and the severityof SARS-CoV-2 infection. Cell. 2020 May28;181(5):969–77.

  36. Iglesias E, Thompson R, Carrazana Y, Lobaina Y,García D, Sánchez J, et al. Coinoculation withhepatitis B surface and core antigen promotes aTh1 immune response to a multiepitopic protein ofHIV-1. Immunol Cell Biol. 2006 Apr;84(2):174–83.




2020     |     www.medigraphic.com